A detailed history of Charles Schwab Investment Management Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 315,827 shares of NUVL stock, worth $26.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
315,827
Previous 265,291 19.05%
Holding current value
$26.6 Million
Previous $20.1 Million 60.55%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$67.44 - $112.17 $3.41 Million - $5.67 Million
50,536 Added 19.05%
315,827 $32.3 Million
Q2 2024

Aug 12, 2024

BUY
$62.76 - $81.61 $1.46 Million - $1.9 Million
23,247 Added 9.6%
265,291 $20.1 Million
Q1 2024

May 08, 2024

BUY
$72.35 - $88.99 $373,543 - $459,455
5,163 Added 2.18%
242,044 $18.2 Million
Q4 2023

Feb 06, 2024

BUY
$42.42 - $80.28 $1.65 Million - $3.12 Million
38,895 Added 19.65%
236,881 $17.4 Million
Q3 2023

Nov 08, 2023

BUY
$39.12 - $49.85 $5.14 Million - $6.55 Million
131,296 Added 196.88%
197,986 $9.1 Million
Q2 2023

Aug 09, 2023

BUY
$23.58 - $44.68 $225,778 - $427,811
9,575 Added 16.76%
66,690 $2.81 Million
Q1 2023

May 11, 2023

BUY
$25.42 - $33.52 $13,853 - $18,268
545 Added 0.96%
57,115 $1.49 Million
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $204,407 - $402,725
11,073 Added 24.34%
56,570 $1.68 Million
Q3 2022

Nov 14, 2022

BUY
$13.55 - $19.92 $64,714 - $95,137
4,776 Added 11.73%
45,497 $885,000
Q2 2022

Aug 15, 2022

SELL
$7.4 - $15.07 $27,439 - $55,879
-3,708 Reduced 8.35%
40,721 $553,000
Q1 2022

May 13, 2022

BUY
$11.65 - $19.57 $201,044 - $337,719
17,257 Added 63.51%
44,429 $618,000
Q4 2021

Feb 11, 2022

BUY
$18.01 - $30.1 $20,603 - $34,434
1,144 Added 4.4%
27,172 $518,000
Q3 2021

Nov 16, 2021

BUY
$18.25 - $38.35 $475,011 - $998,173
26,028 New
26,028 $587,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.62B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.